3657 results for «380»
3657 results
Mitral and aortic transcatheter valve-in-valve intervention - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
Live case
An 83-year-old male with AF, CKD (stage 3A), preserved LV function, and a history of AVR (27 mm Magna Ease) and MVR (33 mm Magna) in 2014 presented with symptomatic stenosis of the mitral bioprosthesis. A Sapien 3 valve was implanted in the Magna mitral...
TEER in complex tricuspid regurgitation - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
A 79-year-old male with permanent AF, prior colorectal and prostate cancer, and a Mosaic bioprosthetic mitral valve implanted in 2016, presented with torrential tricuspid regurgitation and preserved LV function.
Three G5 clips were implanted: two anteroseptal (1 XTW and 1 XT) and one posteroseptal XTW.
LIVE Educational Case...
Primary mitral TEER in small anatomy - LIVE case
15 Feb 2026 – From PCR Tokyo Valves 2026
An 89-year-old male with diabetes mellitus, hypertension, chronic kidney disease (eGFR: 46), and CAD with a history of NSTEMI and CTO of the RCA, presented with symptomatic primary mitral regurgitation (P1–P2 prolapse) and preserved LV function (56%).
One Pascal ACE device was implanted.
LIVE Educational Case from Nagoya...
Late-breaking trials of PCR Tokyo Valves 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
This session presents pivotal late-breaking trials from PCR Tokyo Valves 2026, offering one-year outcomes and real-world experiences in transcatheter valve therapies. Highlights include the AltaValve early feasibility study on atrial fixation TMVR, invasive registry insights on prosthesis-patient mismatch post-TAVR, and registry data on tricuspid and mitral...
Hot topics and evidence on structural interventions in 2025 and 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
Delve into the emerging clinical evidence and key hot topics shaping transcatheter interventions for aortic, mitral, and tricuspid valve diseases anticipated to influence clinical practice in 2025 and 2026. This session reviews stroke prevention, valve interventions across the three valves, and integrates recent and upcoming data...
Procedural imaging for tricuspid valve interventions
15 Feb 2026 – From PCR Tokyo Valves 2026
Dedicated to procedural imaging for tricuspid valve interventions, this session elucidates anatomical and pathophysiological features critical for successful transcatheter procedures. It emphasizes technical aspects of TEE and ICE imaging, including 3D multiplanar reconstruction, and offers case-based learning to refine imaging skills and optimize procedural outcomes.
Prevention and management of TAVI complications
14 Feb 2026 – From PCR Tokyo Valves 2026
This session addresses the prevention and management of major complications associated with transcatheter aortic valve implantation (TAVI). Attendees will gain a detailed understanding of mechanisms behind cerebral infarction, haemolysis, valve infolding, pacemaker implantation, and valve migration, along with expert strategies for recognition, decision-making, and bailout techniques...
PCR Tokyo Valves 2026 Welcome Ceremony
14 Feb 2026 – From PCR Tokyo Valves 2026
The Welcome Ceremony marks the commencement of the conference, setting the stage for an engaging and informative program dedicated to advances in cardiology and interventional techniques. It provides attendees with an overview of the event's objectives and highlights the collaborative spirit of the cardiology community.
2026 Andreas Grüntzig Ethica Awardee: Roxana Mehran
20 May 2026
The Andreas Grüntzig Ethica Award – the highest honour in the interventional cardiology community – is presented to individuals who have contributed in an extraordinary way to the PCR mission.
Discover the new Evolut™ PRO+ TAVI System
17 Jun 2021
New data from Optimize PRO interim analysis
From a design built on a proven platform1, the Evolut™ PRO+ system provides the performance and outcomes you need to help patients live life to the fullest.
PANTHER - P2Y12 inhibitor versus aspirin monotherapy in patients with coronary artery disease
30 Aug 2022
Elad Asher provides his take on the PANTHER trial which was presented at the ESC Congress 2022 in Barcelona
Author
The GUIDE-DES Trial - QCA versus IVUS guidance for DES implantation
27 Aug 2023
Quantitative coronary angiography-guidance versus intravascular ultrasound-guidance for drug-eluting stent implantation (GUIDE-DES trial): A multicenter, non-inferiority, randomised-controlled trial
Nicola Ryan provides her take on the final results of GUIDE-DES which were presented by Taeoh Kim during the ESC 2023 congress in Amsterdam.
Note the assumptions in this article are based on the presentation...
Author
On-site computed tomography-derived fractional flow reserve to guide the management of patients with stable coronary artery disease: The TARGET randomized trial
05 Mar 2023
Mirvat Alasnag provides her take on this clinical trial presented by Yundai Chen at the American College of Cardiology Scientific Session (ACC.23/WCC).
Author
Transcatheter vs surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut Low Risk trial
05 Mar 2023
Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.
Author
Implantation of the Portico With FlexNav TAVI System in a patient with aortic stenosis, severe renal impairment, and diffuse iliac atherosclerosis
12 May 2020
Real-world case report illustrating the benefits of the Portico with FlexNav TAVI system.
NOTION-3 - Percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation
01 Sep 2024
Make the most of the insights from Jacob Thomsen Loenborg’s interview with Chiara De Biase and Ali Nazmi Calik’s article to capture the key takeaways from this trial, simultaneously published in the NEJM, presented at the ESC Congress 2024 in London.
Author
Author
Author
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/congress-coverages/esc/2025/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)